| Case Page

 | Case Page |

Case Page

 

Teva Pharmaceutical Industries Limited : American Depositary Shares

Case Summary

Teva Pharmaceutical Industries Limited : American Depositary Shares Securities Litigation

Case Summary

Case Status:    ONGOING    
On or around 04/11/2017 (Ongoing date of last review)

Filing Date: November 06, 2016

According to the law firm press release, the lawsuit alleges throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.

On April 3, 2017, the Court issued an Order consolidating cases and transferring the consolidated action to the District of Connecticut.

Company & Securities Information

Defendant: Teva Pharmaceutical Industries Limited

COMPANY INFORMATION:

Sector: Healthcare
Industry: Major Drugs
Headquarters: Israel

SECURITIES INFORMATION:

Ticker Symbol: TEVA
Company Market: New York SE
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Amram Galmi, et al. v. Teva Pharmaceutical Industries Limited , et al.

COURT: D. Connecticut
DOCKET #: 16-CV-08259
JUDGE: Hon. Terry J. Hatter, Jr
DATE FILED: 11/06/2016
CLASS PERIOD START: 02/10/2015
CLASS PERIOD END: 11/03/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. The Rosen Law Firm, P.A. (New Los Angeles)
    355 South Grand Ave, Suite 2450, The Rosen Law Firm, P.A. (New Los Angeles), CA 90071
    (213) 785-2610 (213) 226-4684 ·
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint for Violation of the Federal Securities Laws 11/06/2016
2 Order 04/03/2017

Reference Complaint

Amram Galmi, et al. v. Teva Pharmaceutical Industries Limited , et al.

COURT: D. Connecticut
DOCKET #: 17-CV-00558
JUDGE: Hon. Terry J. Hatter, Jr
DATE FILED: 04/04/2017
CLASS PERIOD START: 02/10/2015
CLASS PERIOD END: 11/03/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. The Rosen Law Firm, P.A. (New Los Angeles)
    355 South Grand Ave, Suite 2450, The Rosen Law Firm, P.A. (New Los Angeles), CA 90071
    (213) 785-2610 (213) 226-4684 ·
Reference Complaint (REF) Filings:
No Document Title Filing Date
1 U.S. District Court Civil Docket 04/11/2017
 
 

Cases